

(1025)

27th October, 1987.

Dr. W. Forbes,
Scottish Home and Health Department,
Chief Scientist Office,
St. Andrew's House,
EDINBURGH
EH1 3DE.

Dear Bill,

Apologies for the delay in replying to 5/18 [REDACTED]

Comments in terms of the Aims:-

Aim 2 is the key one, but will not be answered by the study, which fails to address the question directly in terms of the risk of hepatitis transmission. It could do this if recipients of ALT/anti Hbc characterized donations were followed up for the development of non A and non B hepatitis, but this is not proposed. The assumption seems to be made that raised ALT levels not accounted for by obesity or alcohol are related to the carriage of non A non B hepatitis. What is the evidence in the UK for this? (The parenthetic statement in para 2 page 2 points out major differences between the biology of non A non B hepatitis in the UK and the USA).

Aim 3. The first part can be calculated without the need for the proposed study. The second part 'evaluating the economies of the effect on donor management' appears in 'Aims' but is not further described or discussed in the application.

A poorly thought out and seriously flawed application.

Yours sincerely,

[REDACTED]